Chemistry:Vanucizumab
From HandWiki
Short description: Monoclonal antibody
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized |
| Target | angiopoietin 2 |
| Clinical data | |
| Other names | RG7221 |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6529H10033N1733O2038S46 |
| Molar mass | 146887.94 g·mol−1 |
Vanucizumab (INN; development code RG7221) is an experimental humanized monoclonal antibody designed for the treatment of cancer.[1][2]
Vanucizumab is a bi-specific monoclonal antibody composed of two different heavy chains and two different light chains. One arm of the antibody binds Angiopoietin-2 (Ang2) and the other is based on bevacizumab (Avastin), binding Vascular Endothelial Growth Factor A (VEGF-A). The antibody is designed to inhibit both VEGF-A and Ang2 simultaneously to offer superior clinical benefit compared to VEGF-A inhibition alone.[citation needed]
This drug was developed by Genentech/Roche.[citation needed]
References
- ↑ Statement On A Nonproprietary Name Adopted By The USAN Council - Vanucizumab, American Medical Association.
- ↑ World Health Organization (2014). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 111". WHO Drug Information 28 (2). https://www.who.int/medicines/publications/druginformation/innlists/PL111.pdf.
 |  |
